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are made possible by the use of inbred strains or genetic ref-
erence populations of mice. Combining the two, a compre-
hensive picture of the various determinants of ageing and 
‘health span’ can be studied in detail, and an appreciation of 
the relevance of results from model organisms to humans is 
emerging. The interactions between genotype and environ-
ment, particularly the psychosocial environment, are poorly 
studied in both humans and model organisms, presenting 
serious challenges to any approach to a personalized medi-
cine of ageing. To increase the success of preventive inter-
ventions, we argue that there is a pressing need for an indi-
vidualized evaluation of interventions such as physical exer-
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 Abstract 
 Research into ageing and its underlying molecular basis en-
ables us to develop and implement targeted interventions 
to ameliorate or cure its consequences. However, the effi-
cacy of interventions often differs widely between individu-
als, suggesting that populations should be stratified or even 
individualized. Large-scale cohort studies in humans, similar 
systematic studies in model organisms as well as detailed 
investigations into the biology of ageing can provide indi-
vidual validated biomarkers and mechanisms, leading to 
recommendations for targeted interventions. Human cohort 
studies are already ongoing, and they can be supplemented 
by in silico simulations. Systematic studies in animal models 
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cise, nutrition, nutraceuticals and calorie restriction mimetics 
as well as psychosocial and environmental factors, separate-
ly and in combination. The expected extension of the health 
span enables us to refocus health care spending on individ-
ual prevention, starting in late adulthood, and on the brief 
period of morbidity at very old age.  © 2015 S. Karger AG, Basel 
 Introduction 
 The need for ageing research is growing rapidly. 
Trends predicted from the EUROPOP survey suggest 
that the proportion of the population aged 65 years and 
over will rise from 17% in 2010 to 30% in 2060, with those 
aged over 80 years increasing from 5 to 12% over the 
same period (http://futurage.group.shef.ac.uk/road-
map.html). The economic and social consequences of 
the fact that the population is ageing therefore cannot be 
overestimated. Slowing down the deleterious processes 
of ageing itself would allow significant benefits beyond 
those of eradicating specific diseases – which, e.g. in the 
case of cancer and stroke, amount to life span extensions 
of just a few years  [1] . Diseases of age, whether cardio-
vascular, neoplastic, pulmonary or cognitive, are increas-
ing in frequency and will be the top 4 causes of death 
worldwide by 2020; 75% of all deaths from these diseases 
occur in people aged 60 years and over, and their inci-
dence rises with age. In other words, for a host of non-
communicable diseases, there is a clear link between the 
underlying processes of ageing and the age-dependent 
accumulation of risk, so that the eradication of one dis-
ease merely makes way for the occurrence of another dis-
ease slightly later  [2–4] . Slowing down ageing itself, and 
addressing its root mechanisms, is expected to increase 
‘health spans’ and to compress the period of age-related 
morbidity, thus tackling goals considered much more 
worthwhile than simply extending the chronological life 
span  [3, 4] . Moreover, for any interventions, the effects 
of genotype and environment (biological and psychoso-
cial) and the interaction between the underlying mecha-
nisms are most important, and their combinatorial ap-
plication should be considered ( fig. 1 ).
 Therefore, based on the recent convergence of per-
sonalized medicine and ageing research in human and 
model organisms, we suggest in this viewpoint paper 
that a successful research agenda for the next decade 
should be based on three pillars ( fig. 2 ): (1) extending, 
Inter-
vention
Activity
Nutrition
• Exercise
• Social
 participation
• Nutraceuticals
• MediterrAsian
 diet
• CR
 mimetics
• Statins, etc.
Mechanistic
validation in
various model
organisms
Supplementing
existing cohort
studies in humans
Systematic studies
in mice (e.g.
Collaborative
Cross)
 Fig. 1. Health span extension includes activity, diet and other in-
terventions, each of which are expected to be most effective if per-
sonalized (alone and in combination). For the ‘MediterrAsian’ 
diet, see  [67] . CR = Calorie restriction. 
 Fig. 2. Robust research on health span extension requires a solid 
base of systematic studies in humans and animals and an under-
standing of the biology of ageing, that is, of the mechanisms un-
derlying molecular ageing processes. 
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complementing and integrating the knowledge base as-
sembled in existing human cohort studies; (2) running 
closely similar studies in animal models, and (3) under-
standing the biology of ageing through the detailed in-
vestigation of findings in humans and animals to gain a 
mechanistic understanding of biomarkers and interven-
tions. 
 Our agenda rests on the biomarker concept. Baker 
and Sprott  [5] defined a biomarker of ageing as ‘a bio-
logical parameter of an organism that either alone or in 
some multivariate composite will, in the absence of dis-
ease, better predict functional capability at some late age, 
than will chronological age’; the American Federation 
for Aging Research has proposed more detailed criteria 
for biomarkers of ageing aimed at estimating biological, 
not chronological age  [6] , essentially adding their close 
relation to processes that underlie ageing, not disease, 
their ease of measurement and their cross-species rele-
vance. However, while many biomarkers of ageing were 
described in animal or cross-sectional human studies, 
most of them failed in the few long-term human studies 
available  [7] . One problem lies in technical limitations: 
human marker measurements are rarely comparable 
across decades. Also, by selecting blood as the most eas-
ily assayable biological fluid, other organs affected by age 
are ignored. Moreover, there are major variations during 
the day or the year, as e.g. the amount of daylight will 
have an impact on many markers. Also, some markers 
such as a low body mass index or blood pressure may in-
dicate a lower biological age for younger people and the 
opposite for the very old  [8, 9] . Finally, while biomarkers 
should describe biological age, there is no true ‘gold stan-
dard’ – which would need to be based on a comprehen-
sive longitudinal study in humans running for almost a 
century. Studies of populations at an advanced age, such 
as the Leiden or Newcastle 85+ studies  [10, 11] , necessar-
ily focus on old-age multimorbidity rather than on the 
full spectrum of ageing processes over a human life 
course. Nevertheless, listings of biomarkers validated for 
humans in longitudinal studies were compiled; they in-
clude interleukin 6 (IL-6) and some hormones  [7, 12] , 
as well as, more recently, galactosylated N-glycans  [13] , 
plasma N-terminal pro-B-type natriuretic peptide  [14] 
and epigenetic markers  [15, 16] .
 ‘Personalized’ approaches to medicine are gaining 
ground in mainstream medical research. The most well-
known of these involve cancer therapeutic agents with a 
companion diagnostic gene test, such as Herceptin TM and 
Gleevec TM  [17] . More comprehensive, ‘omics’-based at-
tempts at personalizing diagnostics and therapy are be-
ing tested  [18] . Moreover, molecular markers and inter-
ventions have to be integrated with biographical ones 
 [19] . Assembling sufficiently large human data sets in or-
der to allow a differentiation and classification of patients 
within cohorts is the key to personalized medicine. Lon-
gitudinal cohort studies, such as the Framingham Heart 
Study  [20] and the Study of Health in Pomerania (SHIP) 
 [21] or the upcoming German National Cohort  [22] , 
therefore attempt to identify disease mechanisms, risk 
factors, prevention strategies and early markers in the 
general population; systematic integration of such data is 
also being attempted (http://www.chancesfp7.eu/).
 While the mechanisms of ageing are complex  [4, 23, 
24] , evidence is accumulating that ageing is a potential-
ly modifiable risk factor  [25] for morbidities associated 
with it. Moreover, longitudinal cohort studies in hu-
mans (see above) and primates  [26, 27] , human genome-
wide association studies  [28] as well as longitudinal 
studies, genetic manipulation and intervention testing 
programs for rodents  [29–31] have yielded many in-
sights in recent years. Some of them converge on exer-
cise and diet and their associated pathways. In particu-
lar, one of the recurring themes is that of pathways re-
lated to energy and nutrient sensing and production 
 [32] , and dietary restriction has emerged as the most ro-
bust means of extending life spans and health spans alike 
 [26] . Dietary restriction may be the best path towards 
this goal, even though its long-term effects on humans 
are ultimately unknown. Pragmatically speaking, its 
downside is that it requires behavioral modifications 
and great willpower, triggering the search for calorie-
restriction mimetics, i.e. small molecules that produce 
comparable effects, with some of them promising early 
results  [33] . Importantly, the effects of dietary restric-
tion are not uniform; in the case of mice and primates, 
the results of dietary restriction vary by genotype (or 
strain or subspecies), diet and/or environment, and di-
etary restriction was sometimes found to be detrimental 
 [34] , just as the effects of its mimetics vary  [35] . The ef-
fects of dietary components vary as well; for instance, 
whole-grain bread tends to have positive effects mostly 
in Northern European populations and less in Mediter-
ranean people  [36] . Similarly, the effects of fish oil in 
mice and humans depend on the  APOE genotype  [37] . 
Thus, we may expect to find a high degree of heteroge-
neity in the informativity of biomarkers, or the efficacy 
of interventions, for humans and outbred animals alike. 
Moreover, studies of the underlying molecular mecha-
nisms in terms of pathways may also wish to take into 
account individual variability.
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 Personalized Medicine and Ageing Research 
Are Now Starting to Come Together, 
Aided by the Explorative and Confirmatory Power of 
High-Throughput Data Sets 
 The most visible sign of the convergence of personal-
ized medicine and ageing research is the recent start-up 
of Human Longevity Inc. (http://www.humanlongevity.
com/) by Craig Venter, aiming at finding genomic, me-
tabolomic, microbiomic and other determinants of health 
in hundreds of thousands of volunteers. Along similar 
lines, the Institute for Systems Biology in Seattle is now 
pursuing the 100K Wellness Project (http://research.
systemsbiology.net/100k/). As time goes by, longitudinal 
cohort studies will by necessity be developing into studies 
of ageing, and a few are explicitly gathering data with the 
aim of fostering a better understanding of ageing process-
es  [38, 39] . Longitudinal studies in model organisms per-
mit a systematic dissection of the molecular architecture 
of ageing. For example, around 30 strains of mice have 
recently been studied at the Nathan Shock Center of the 
Jackson Laboratory  [29] , and phenotypic and/or genetic 
data are now being analyzed together with life span data 
 [9, 40, 41] . Efforts such as the Collaborative Cross  [42] al-
low genome-wide association study-like trials in mice as 
well as the subsequent detailed study of mechanistic in-
sights and, more generally, the modeling of approaches to 
personalized medicine in animals. Here, we can investi-
gate in great detail the individual differences in the biol-
ogy of ageing on the cell, tissue and organ level. On each 
of these levels, the speed of ageing can vary substantially, 
and this may, for instance, be reflected epigenetically  [15, 
16] . More generally, as described in the Introduction, bio-
markers of ageing are usually found while investigating 
subpopulations (such as people aged 85 years and older), 
and these biomarkers also allow the stratification of large 
populations according to the biology of ageing.
 Whilst association studies may provide information 
on personal risks for specific morbidities as well as on 
their severity and timing, many of these risks are turning 
out to be modified by subjects’ psychosocial environment 
and individual history, which in themselves need to be 
included not only as part of the risk analysis but also as a 
guide to potential therapies  [43] . Many associations with 
ageing and age-related diseases such as Alzheimer’s are 
complex, often with low effect sizes of individual variants, 
and it is highly likely that at least some of the missing 
heritability is due to environmental interactions  [44] . For 
example, in a mouse model, the disease risk in predis-
posed strains was shown to be attenuated by environmen-
tal factors when Alzheimer-prone mice were placed in a 
rich and naturalistic environment, showing reduced be-
havioral effects despite increased plaque density  [45] . 
Moreover, the induction of a neuroinflammatory re-
sponse was related to chronic unpredictable stress  [46] . 
Conversely, dopamine receptor D 4  (DRD4) knockout 
mice do not show the increased longevity observed when 
background strain mice are brought up in a rich environ-
ment, showing them to be refractory to the positive effects 
of a rich environment. This study showed consistency 
with a parallel human cohort, presenting an excellent par-
adigm for future work  [47] . An individual environmental 
impact may be reflected epigenetically  [15] . Such epige-
netic individuality is influenced in part by biographical 
parameters, reflecting the psychosocial environment, so-
cial participation and education, and the way this allo-
static load has been handled by the individual as part of 
her or his stress response. In turn, targeted interventions 
may be used to ameliorate the environment  [19] .
 Apart from ‘omics’ data processing and analysis, com-
putational studies permit well-founded comparisons of 
human and animal data, as well as simulation studies, 
particularly on the molecular level. At its simplest, the 
parallelogram approach, originally developed in toxicol-
ogy  [48] , suggests the use of data from diseased animal 
tissue to extrapolate them to the often inaccessible human 
diseased tissue, aided by e.g. blood data available for dis-
eased and healthy individuals. Moreover, controlled vo-
cabularies and ontologies, describing the formal relation-
ships between concepts and entities, are developed to al-
low the systematic comparison of human and animal data 
 [49] . For example, on the (cell) anatomical and physio-
logical level, we can then integrate data and analyze the 
relationship between phenotypes of humans and model 
species, yielding estimates for the extrapolation of data 
and insights from model organisms to humans. Formal 
data semantics is also useful to systematically mine elec-
tronic health record data in order to describe phenotypes 
and diseases  [50] . Furthermore, recent promising devel-
opments in systems biology and systems medicine in-
clude simulation studies of ageing-related pathways and 
multilevel modeling of the large number of interacting 
processes involved  [51] . Such studies help to disentangle 
the network of interdependent biological processes that 
underlie ageing, and to distinguish between correlation 
and causality, following the example of cancer research, 
where computational studies help to distinguish ‘passen-
ger’ from ‘driver’ mutations  [52] . Whereas many cancers 
are characterized by gross modifications of cell and organ 
physiology (e.g. due to chromosomal aberrations), ageing 
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processes are subtler, triggering weaker patterns and sig-
nals in terms of phenotype and molecular mechanisms, 
and on a longer timescale. Therefore, the sound integra-
tion of data using the techniques of data semantics and 
ontologies is important in ageing research  [53–56] to 
maximize our chances of detecting meaningful patterns 
and signals.
 The Implementation of Any Recommendations for 
Health Span Extension Must Be Easy and Safe 
 Many people show close adherence to moderate mod-
ifications of exercise and dietary patterns, motivated by 
their personal instinct or subjective feelings of benefit. 
The correct use of and long-term adherence to changes in 
dietary composition, nutraceuticals and food supple-
ments is more difficult, though. 1 Healthy and health-con-
scious individuals consuming high amounts of fruit and 
vegetables (>400 g/day) display a more robust organismal 
antioxidant defense system  [57] and a better cognitive 
performance  [58] , independent of their age and gender, 
compared to subjects consuming <100 g/day, although 
a good plasma micronutrient status can be achieved 
through targeted counseling  [59] . However, as the correct 
use of nutraceuticals and food supplements is complicat-
ed  [60] , most of the supplementation trials with single 
compounds and/or single lifestyle preventive strategies 
against age-related diseases have largely been unsuccess-
ful so far  [61] . Furthermore, an immediate subjective feel-
ing of benefit with nutraceuticals is not usually attained, 
while their possible physiological impact may be signifi-
cant (on the positive as well as on the negative side). This 
also applies to long-term small-molecule interventions 
such as calorie-restriction mimetics. Additionally, the 
quality and safety of nutraceuticals and food supplements 
are not controlled as strictly as drugs. Here, subjective 
feelings have to be supplemented with or substituted by 
sound scientific evidence regarding benefits, subject to a 
personalized approach. The polypill concept  [62] is often 
criticized exactly because it does not consider the specif-
ics of the individual. It consists of intensively tested drugs 
at low dosage, the benefits of which have been shown in 
large-scale studies. Specifically, it aims to reduce the risk 
of heart attacks and strokes, employing one statin and 
three blood pressure-reducing agents at around half the 
standard dose; in a personalized instantiation, it can be 
considered a model for active interventions to stay healthy 
for longer periods of time.
 Sound Scientific Evidence for Health Span Effects of 
Interventions in Humans Is Becoming Available 
 Conclusive evidence for therapeutic or prophylactic 
effects of interventions on the human health span is going 
to be difficult to establish, since longitudinal intervention 
studies (starting in midlife) would take around half a cen-
tury to complete. Moreover, interventions designed for 
presumably healthy people need specific justification and 
should have no discernible negative side effects. Howev-
er, a significant postponement of ageing-associated dis-
ease and morbidity is a distinctly positive aim that should 
not be abandoned without due consideration. Fortunate-
ly, there are a couple of convincing arguments that indi-
cate a high likelihood of success in finding valid means 
for achieving health span extensions  [25] , with people in 
their late adulthood as the target group. First, very ‘mild’ 
forms of health span-extending interventions have al-
ready been practiced for a long time; their systematic and 
personalized improvement is already half the battle. Such 
interventions include exercise, diet and nutraceuticals, as 
well as indication-based interventions such as drug-based 
blood pressure reduction, cholesterol modulation and os-
teoporosis prevention. Also, for many individuals, a fur-
ther significant extension of their health span can be ex-
pected from improvements in their psychosocial envi-
ronment, social participation and education. While 
consistent good parental care in the early years is a good 
foundation, psychosocial lifestyle interventions can still 
be effective in adulthood  [19] . Second, as a proof of con-
cept, dietary restriction has already been demonstrated to 
extend health spans in numerous animal species includ-
ing mammals – benefitting rhesus monkeys, for example 
(see above) – and has been shown to improve biomarkers 
of ageing in humans in late adulthood as well  [63] . More-
over, as described above, pharmacological mimetics of di-
etary restriction have shown promising results, at least in 
mouse studies  [33] . Combining interventions is impor-
tant, though, since most of the supplementation trials 
with single compounds and/or single lifestyle preventive 
strategies have largely been unsuccessful so far  [61] . 
Third, centenarians frequently feature very late onsets of 
age-related diseases and disabilities  [64] , demonstrating 
that the goal of health span extension can indeed be ac-
complished at a very old age.
 1   For example, a 6-year study on the prevention of dementia failed to show 
positive effects, possibly due to increasing nonadherence  [68] (fig. 2 therein). 
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 Conclusions and Prospects 
 We propose a realistic research agenda with distinctive 
positive advances within one decade:
 • We need to augment ongoing and future clinical stud-
ies, measuring as many ageing-related parameters as 
possible, and to couple them with closely similar animal 
studies, which feature far shorter execution times and 
more possibilities for experimental intervention and 
detailed study. Here, one main aim is to discover and 
validate new markers of ageing which may assist in the 
stratification of populations with regard to the efficacy 
of therapeutic and prophylactic interventions. It is crit-
ical to record environmental parameters as well as the 
characteristics of stress, activity and personal history for 
human studies and to conduct detailed analyses of the 
effects of the environment for model organism studies. 
 • We need to systematically validate the evidence gained 
from model animal studies in humans and vice versa. 
Here, we need an in-depth understanding of the mo-
lecular processes that are supposed to be the targets of 
an intervention. Mechanistic studies in mice are essen-
tial, and studies in humanized mice, (human) cell lines 
and other model organisms should be undertaken as 
well, always selecting the most informative approach. 
 • Finally, given the range of interventions likely to be-
come validated and available, we should aim for a com-
binatorial approach through the establishment of a 
modular system, from which the most appropriate 
combination of interventions ( fig. 1 ) can be selected by 
any individual. 
 Such an agenda can be expected to yield validated person-
alized prescriptions for many people within a decade, en-
abling them to extend their health span and to shorten the 
period of their life that is spent in ill health.  
 Economic Implications 
 Slowing ageing and extending health spans has pro-
found economic implications. Importantly, maintaining 
health and fitness for a longer time period allows later 
retirement and more senior-level contributions to society 
(http://www.healthyageing.eu/). Furthermore, with the 
growing shortage of young employees there is a great 
need for people working until the age of 70 years or more, 
especially in service industries such as medicine. Most 
importantly, however, increases in health span are among 
the few contributors to lowering health care costs in a 
predictable way by postponing most of the demand until 
very old age  [65] . The current repair-oriented approaches 
adopted in cancer, cardiovascular diseases, neurodegen-
eration and other areas may then slowly but steadily be 
refocused on serving populations at an increasingly ad-
vanced age who stay healthy well beyond their 90s. In 
summary, the social, economic and health-related bene-
fits resulting from prolonging health spans are ‘longevity 
dividends’  [66] .
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